摘要
目的探讨托伐普坦治疗顽固性心力衰竭伴低钠血症患者的疗效。方法 80例顽固性心力衰竭伴低钠血症患者,随机分为对照组和试验组,各40例。对照组采取常规治疗,试验组在对照组基础上采用托伐普坦治疗,比较两组患者的治疗效果。结果试验组患者24 h尿量、N-末端B型利钠肽前体(NT-pro BNP)、血钠、血钾、血肌酐均优于对照组,差异有统计学意义(P<0.05),试验组患者左心室射血分数(LVEF)为(28.36±5.11)%,对照组为(28.33±5.13)%,比较差异无统计学意义(P>0.05)。结论托伐普坦可以有效治疗顽固性心力衰竭伴低钠血症患者,提高血钠水平,值得临床推广。
Objective To discuss the efficacy of tolvaptan in treatment of patients with refractory heart failure and hyponatremia. Methods A total of 80 patients with refractory heart failure and hyponatremia were randomly divided into control group and experimental group, with 40 cases in each group. The control group was treated with conventional therapy, and the experimental group was treated with tolvaptan on the basis of the control group. The treatment effect in two groups was compared. Results The experimental group had better 24 h urine volume, N-terminal pro B type natriuretic peptide （NT-proBNP）, blood sodium, blood potassium, and blood creatinine than the control group, and the difference was statistically significant （P〈0.05）. The experimental group had left ventricular ejection fraction （LVEF） as （28.36±5.11）%, which was （28.33±5.13）% in the control group, and the difference was not statistically significant （P〉0.05）. Conclusion Tolvaptan is effective in treating patients with refractory heart failure and hyponatremia, and improve serum sodium level. It is worthy of clinical promotion.
出处
《中国现代药物应用》
2018年第3期65-66,共2页
Chinese Journal of Modern Drug Application
